Portal de Periódicos da CAPES

Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study

2024; Elsevier BV; Volume: 199; Linguagem: Inglês

10.1016/j.ejca.2024.113542

1879-0852

Mario Mandalà, Paul Lorigan, Maria Chiara Sergi, Naima Benannoune, Patricio Serra, Maria Grazia Vitale, Diana Giannarelli, Ana Arance, Eva Muñoz‐Couselo, Bart Neyns, Marco Tucci, Michele Guida, Francesco Spagnolo, Ernesto Rossi, Marcella Occelli, Paola Queirolo, Pietro Quaglino, Roberta Depenni, Barbara Merelli, Joanna Placzke, Anna Maria Di Giacomo, Michele Del Vecchio, Alice Indini, Inês Pires da Silva, Alexander M. Menzies, Georgina V. Long, Caroline Robert, Piotr Rutkowski, Paolo A. Ascierto,

Cancer Immunotherapy and Biomarkers

Ipilimumab plus nivolumab (COMBO) is the standard treatment in asymptomatic patients with melanoma brain metastases (MBM). We report a retrospective study aiming to assess the outcome of patients with MBM treated with COMBO outside clinical trials.